This study supports the model that GSK3 inhibition activates NF-κB, which leads to TNF-α production, induction of cell surface receptors, enhanced conjugate formation and subsequent AML cell killing (Fig. 6d). The gene discussed is CD177; the disease is acute myeloid leukemia.